Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Intra-Cellular Therapies Inc Market Cap
Based on ratings from 8 stock analysts, the Intra-Cellular Therapies Inc stock price is expected to increase by 24.99% in 12 months. This is calculated by using the average 12-month stock price forecast for Intra-Cellular Therapies Inc. The lowest target is $68 and the highest is $130. Please note analyst price targets are not guaranteed and could be missed completely.
ITCI is a stock in Health Care which has been forecasted to be worth $94.24 as an average. On the higher end, the forecast price is $130 USD by Charles Duncan from Cantor Fitzgerald and on the lower end ITCI is forecasted to be $68 by from .
These are the latest 20 analyst ratings of ITCI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jessica Fye JP Morgan | Overweight | $81 | Maintains | Aug 21, 2024 |
| Ashwani Verma UBS | Neutral | $79 | Maintains | Aug 8, 2024 |
| Corinne Jenkins Goldman Sachs | Neutral | $74 | Maintains | Aug 8, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $130 | Maintains | Aug 8, 2024 |
| Brian Abrahams RBC Capital | Outperform | $106 | Maintains | Aug 8, 2024 |
| Ami Fadia Needham | Buy | $100 | Reiterates | Aug 8, 2024 |
| Ami Fadia Needham | Buy | $100 | Reiterates | Aug 7, 2024 |
| Ami Fadia Needham | Buy | $100 | Maintains | Jul 22, 2024 |
| Brian Abrahams RBC Capital | Outperform | $103 | Reiterates | Jun 25, 2024 |
| Ashwani Verma UBS | Neutral | $83 | Downgrade | Jun 25, 2024 |
| Graig Suvannavejh Mizuho | Buy | $100 | Maintains | Jun 21, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $113 | Maintains | Jun 20, 2024 |
| Ami Fadia Needham | Buy | $94 | Maintains | Jun 18, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $120 | Reiterates | Jun 14, 2024 |
| Jessica Fye JP Morgan | Overweight | $78 | Maintains | Jun 12, 2024 |
| Ami Fadia Needham | Buy | $90 | Reiterates | May 8, 2024 |
| Ami Fadia Needham | Buy | $90 | Reiterates | May 7, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $120 | Reiterates | Apr 24, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $107 | Maintains | Apr 23, 2024 |
| Ami Fadia Needham | Buy | $90 | Maintains | Apr 22, 2024 |
When did it IPO
N/A
Staff Count
610
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Dr. Sharon Mates Ph.D.
Market Cap
$7.81B
In 2023, ITCI generated $462.2M in revenue, which was a increase of 85.51% from the previous year. This can be seen as a signal that ITCI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 06 Sep 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Intra-Cellular (ITCI) reported earnings 30 days ago; investors should monitor developments for potential impacts on the stock's performance moving forward.
Why It Matters - Earnings reports can indicate company performance and future growth, affecting stock prices. Investors need to assess ITCI's earnings impact on its valuation and market outlook.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) CEO Sharon Mates, Ph.D., will present at three upcoming investor conferences, focusing on CNS disorder therapeutics.
Why It Matters - Sharon Mates' presentations may signal strategic updates, insights on drug development, or financial guidance, potentially impacting Intra-Cellular's stock performance and investor sentiment.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Investors Business Daily
Summary - A biotech stock is stabilizing at a moving average, with decreasing losses and analysts predicting future profitability.
Why It Matters - The biotech stock's potential for profit and technical support at a moving average indicate a possible turnaround, attracting investor interest and signaling a favorable entry point.
Thu, 08 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Intra-Cellular (ITCI) reported Q2 2024 earnings and revenues that exceeded estimates, fueled by robust sales of Caplyta.
Why It Matters - Intra-Cellular's better-than-expected earnings and revenues, fueled by strong Caplyta sales, suggest strong business performance, potentially boosting investor confidence and stock value.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Intra-Cellular Therapies CEO Sharon Mates will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 12:00 p.m. ET in Boston.
Why It Matters - Sharon Mates' presentation at a prominent conference could signal potential company developments and attract investor interest, impacting stock performance and market perception.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) held its Q2 2024 earnings call on August 7, 2024, featuring key executives and analysts from major financial firms.
Why It Matters - Earnings calls provide insights into a company's financial health and strategic direction, impacting stock performance and investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
